Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2002-10-04
2010-10-12
Gambel, Phillip (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S388100, C530S388150, C530S388200, C530S388700
Reexamination Certificate
active
07812136
ABSTRACT:
The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.
REFERENCES:
patent: 6265150 (2001-07-01), Terstappen et al.
patent: 6790938 (2004-09-01), Berchtold et al.
patent: 6955900 (2005-10-01), Barbas et al.
patent: 2003/0219434 (2003-11-01), Carter et al.
patent: 0 557 535 (1992-09-01), None
Schwarz et al., The FASEB Journal 18:12 express article 10.1096/fj.04-151fje, published online Sep. 16, 2004.
Rudikoff et al., Proc Natl Acad Sci USA 79: 1979-1983, 1982.
Colman, Research in Immunology 145: 33-36, 1994.
Kussie et al., J. Immunol. 152: 146-152, 1994.
Chen et al., EMBO J., 14: 2784-2794, 1995.
Nurden et al., Blood 88: 887-899, 1996.
Schwarz et al., The FASEB Journal express article 10.1096/fj.O4-1513fje. Published online Sep. 16, 2004.
Chung et al. The FASEB Joumal express article 10.1096/fj.03-0586fje. Published online Dec. 19, 2003.
Bedner, et al., “Identification of Low Molecular Weight GP Iib/Iia Antgonists That Bind Preferentially to Activated Platelets”,M. Pharmacology, 285(3):1317-1326 (1998).
Berkowitz. “Current knowledge of the Platelet Glycoprotein Iib/IIIa Receptor Antagonists for the Treatment of Coronary Artery Disease”,Haemostatis30(Supp 3):27-43 (2000).
Bhatt and Topol, “Current Role of Platelet Glycoprotein Iib/IIIa Inhibitors in Acute Coronary Syndromes”.JAMA284(12):1549-1558 (2000).
Chew, et al., “Increased Mortality with Oral Platelet Glycoprotein IIb/IIIa Antagonists”,Circulation103(2):201-206 (2001).
Cohen, “Platelet Glycoprotein IIb/IIIa Receptor Inhibitors in Coronary Artery Disease”,Ann Intern. Med. 124:843-844 (1996).
Colcher, et al, “Characterization an Biodistribution of Recombinant and Recombinatn/Chimeric Constructs of Monoclonal Antibody B72.3”,Cancer Research49:1732-1745, (1989).
Coller, et al, “A Murine Monoclonal Antibody That Completely Blocks the Binding of Fibrinogen to Platelets Produces a Thrombasthenic-like State in Normal Platelets and Binds to Glycoproteins Iib and/or IIIa”.J. Clin. Invest. 72:325-338 (1983).
Davis, “Advances in the use of recombinant baculoviruses for the expression of heterologous proteins”,Curr. Opin. Biotech6:543-547 (1995).
Domesh, et al., “Advancing the Battle Against Acute Ischemic Syndromes: A Focus on the GP Iib-IIIa Inhibitors”,Pharmacology18(4):663-685 (1998).
Gawaz, M., Therapie bei koronarer Herzerkrankurg Stuttgart, New York, Thieme (1999), Table of Contents only.
Hillegass, et al., Glycoprotein Iib/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non-ST-Segment Elevation Acute Coronary Syndromes,Pharmacoeconomics19(1):41-55 (2001).
Holmgren, “Thioredoxin”,Ann. Rev. Biochem, 54:237-271 (1985).
Hoogenboom and Chames, “Natural and designer binding sites made by phage display technology”,Imm. Today21(8):371-377 (2000).
Jacobin, et al., “Human IgG Monoclonal Anti-α5bβ3-Binding Fragments Derived from Immunized Donors Using Phage Display”,J. Immun. 168:2035-2045 (2002).
Jubellner, et al., “Acute Profound Thromobocytopenia Following C7E3 Fab (Abciximab) Therapy: Case Reports, Review of the Literature and Implications for Therapy”,Am. J. Hematol. 61:205-208 (1999).
Kunick; et al., “A Molecular Basis for Affinity Modulation of Fab Ligand Binding to Intergrin α5bβ3”,J. Bio. Chem. 271(34):20315-20321 (1996).
LaVallie, et al., “A Thioredoxin Gene Fusion Expression System That Circumvents Inclusion Body Formation in theE. coliCytoplasm”,Biotechnology11:187-193, 1993.
Nguyen-Ho and Lakkis, “Platelet Glycoprotein Iib/IIIa Receptor Antagonists and Coronary Artery Disease”,Current Astherosclerosis Reports3:139-148 (2001).
Peter, et al., “Induction of Fibrinogen Binding and Platelet Aggregation as a Potential Intrinsic Property of Various Glycoprotein Iib/IIIa (α5bβ3) Inhibitors”, Blood 92(9):3240-3249, 1998.
Sambrook, et al., Molecular Cloning—A Laboratory Manual, Cold Spring Harbor (1989), pp. XI-XXXVIII only.
Shattil, et al., “Changes in the Platelet Membrane Glycoprotein IIb IIIa Complex during Platelet Activation”,J. Bio. Chem. 260(20):11107-11114 (1985).
Suzuki, et al., “Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys”,European J. Phar. 336:169-176 (1997).
Topol, et al., “Platelet GPIIb-IIIa blockers”,Lancet353(9148):227-231, 1999.
Wong, “Advances in the use ofBacillus subtilisfor the expression and secretion of heterologous proteins”,Curr. Opin. Bio. 6:514-522 (1995).
Buettner Claudia
Knackmuss Stefan
Little Melvyn
Peter Karlheinz
Roettgen Peter
Affimed Therapeutics AG
Gambel Phillip
Howrey LLP
LandOfFree
Antibody of human origin specifically binding to activated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody of human origin specifically binding to activated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody of human origin specifically binding to activated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4172338